Century Therapeutics (IPSC) Non-Current Debt (2020 - 2022)

Century Therapeutics (IPSC) has 3 years of Non-Current Debt data on file, last reported at $3.7 million in Q4 2022.

• On a quarterly basis, Non-Current Debt fell 58.0% year-over-year to $3.7 million in Q4 2022; TTM through Dec 2022 was $3.7 million, a 58.0% decrease from a year earlier, with the FY2022 full-year figure at $3.7 million, down 58.0% from the prior year.
• Non-Current Debt for Q4 2022 stood at $3.7 million, down from $6.1 million in the prior quarter.
• Over the last five years, Non-Current Debt for IPSC reached as high as $10.0 million in Q1 2022 and fell as low as $3.7 million in Q4 2022.
• Historically, Non-Current Debt has averaged $7.8 million across 3 years, with a median of $8.7 million in 2021.
• Across the five-year window, Non-Current Debt decreased 7.61% in 2021 and tumbled 58.0% in 2022, its largest moves.
• Year by year, Non-Current Debt stood at $9.6 million in 2020, then slipped by 7.61% to $8.9 million in 2021, then tumbled by 58.0% to $3.7 million in 2022.
• Per Business Quant data, the three most recent Non-Current Debt figures were $3.7 million in Q4 2022, $6.1 million in Q3 2022, and $8.5 million in Q2 2022.